Condition
Neoplasm Recurrence
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 3 (1)
P 4 (1)
Trial Status
Completed2
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05037279Phase 3Recruiting
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
NCT06046131Not ApplicableRecruiting
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
NCT01696565Phase 1Completed
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
NCT04653818Phase 4Completed
HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
Showing all 4 trials